Bluebird ' s lovo-cel application finally lands at the FDA ' s desk

After being hit with a partial clinical hold for its gene therapy back in | After a partial clinical hold caused bluebird to miss its own first-quarter FDA filing goal, the company says its sickle cell disease gene therapy application is in.#fda
Source: Reuters: Health - Category: Consumer Health News Source Type: news